Abstract
To assess clinical utility of the 21-gene assay (Oncotype DX® Recurrence Score®), we determined whether women with HER2(-)/ER+ pN1mi breast cancer with low (<18) Recurrence Scores results are given adjuvant chemotherapy in a lower proportion than those with high scores (≥31). This was a multicenter chart review of ≥18 year old women with pN1mi breast cancer, HER2(-)/ER+ tumors, ductal/lobular/mixed histology, with the assay ordered on or after 1 January 2007. One hundred and eighty one patients had a mean age of 60.7 years; 82.9% had ECOG performance status 0; 33.7% had hypertension, 22.7% had osteoporosis, 18.8% had osteoarthritis, and 8.8% had type-2 diabetes. Mean Recurrence Score was 17.8 (range: 0-50). 48.6% had a mastectomy; 55.8% had a lumpectomy. 19.8% of low-risk group patients were recommended chemotherapy vs. 57.9% in the intermediate-risk group and 100% in the high-risk group (p < 0.001). A total of 80.2% of the low-risk group were recommended endocrine therapy alone, while 77.8% of the high-risk group were recommended both endocrine and chemotherapy (p < 0.001). The Oncotype DX Recurrence Score result provides actionable information that can be incorporated into treatment planning for women with HER2(-)/ER+ pN1mi b...Continue Reading
References
Sep 8, 2004·Lancet·Bernard FisherUNKNOWN National Surgical Adjuvant Breast and Bowel Project randomised clinical trials
Dec 14, 2004·The New England Journal of Medicine·Soonmyung PaikNorman Wolmark
Dec 29, 2004·Annals of Surgery·Igor LangerMarkus Zuber
Apr 13, 2006·JAMA : the Journal of the American Medical Association·Donald A BerryEric P Winer
May 25, 2006·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Soonmyung PaikNorman Wolmark
Jun 13, 2006·European Journal of Surgical Oncology : the Journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology·M van der Heiden-van der LooP H M Peeters
Jan 9, 2007·The Breast : Official Journal of the European Society of Mastology·C SkedgelT Younis
Feb 9, 2008·Breast Cancer Research and Treatment·A J G MaaskantG A P Nieuwenhuijzen
Mar 26, 2009·Journal of the American College of Surgeons·Jennifer ReedLorraine Tafra
Jun 30, 2009·Breast Cancer Research and Treatment·E MontagnaM Colleoni
Aug 14, 2009·The New England Journal of Medicine·Maaike de BoerVivianne C G Tjan-Heijnen
Sep 2, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Nora M HansenArmando E Giuliano
Dec 17, 2009·The Lancet Oncology·Kathy S AlbainUNKNOWN Breast Cancer Intergroup of North America
Feb 26, 2010·Annals of Surgical Oncology·Sonia PernasMiguel Gil Gil
Mar 10, 2010·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Mitch DowsettSteven Shak
Apr 9, 2010·Anti-cancer Drugs·Sandra GeigerHans-Joachim Stemmler
Jun 29, 2010·Annals of Oncology : Official Journal of the European Society for Medical Oncology·D BovelliUNKNOWN ESMO Guidelines Working Group
Jul 27, 2011·Surgical Oncology·Mohamed SalhabKefah Mokbel
Sep 3, 2011·Journal of Oncology Practice·John HornbergerLouis Hochheiser
Dec 22, 2011·Journal of the National Comprehensive Cancer Network : JNCCN·Phillip G FebboMarian L Birkeland
Dec 6, 2011·Journal of the National Cancer Institute·Peter S HallDavid Cameron
Feb 24, 2012·Cancer·Mo YangAmalia M Issa
Citations
Apr 5, 2013·PloS One·Jessica M StilesBrad A Bryan
Mar 28, 2019·Cancer Research and Treatment : Official Journal of Korean Cancer Association·Wei-Rong ChenSan-Gang Wu
Jul 1, 2018·World Journal of Surgery·Hyeon Woo BaeByeong-Woo Park
Jun 27, 2018·Biomedicine & Pharmacotherapy = Biomédecine & Pharmacothérapie·R L N GodoneD B G Martins